The "Halftime Report" experts discuss BTIG's Celgene upgrade
Biotech stocks have seen a big bounce in the past few weeks, as the group hits its highest level since January. Talking biotech, with David Seaburg, Cowen, and Chad Morganlander, Stifel Nicolaus.
The “Fast Money Halftime Report” traders share their views on Scotts Miracle-Gro and Celgene. Dane Leone, BTIG analyst, weighs in on Celgene.
Biotech hits a 6-month high. The "Fast Money Halftime Report" traders discusses whether they think it's time to buy biotech.
The "Fast Money" traders discuss their views on Biogen.
Jim Cramer reviewed the recent bullish actions taken by Tesla and Uber, and says it could mean big things for historically difficult August.
Michael Yee, RBC analyst, shares his views on the biotech breakout. The "Fast Money" traders weigh in.
CNBC's Jim Cramer explains why he is watching Celgene.
The "Fast Money" traders share their final trades of the day, including Tesoro, Celgene and more.
U.S. biotechnology company Celgene reported a 21 percent jump in quarterly revenue, driven by demand for its key multiple myeloma drug, Revlimid.
CNBC's Meg Tirrell reports the latest earnings results for AstraZeneca, Bristol-Myers and Celgene.
Some of the names on the move ahead of the open.
In a world of disappearing market returns and negative interest rates, the search for growth has become increasingly difficult, Goldman Sachs says.
U.S. Stocks closed higher Wednesday as Wall Street celebrated better-than-expected earnings off of a record week of gains for the Dow.
The Credit Suisse research team presented its highest-conviction stock ideas in a note to clients Friday.
Check out the companies making headlines after the bell Thursday: Juno Therapeutics, GAP, BioMarin Pharmaceutical and more.
CNBC's Meg Tirrell reports the latest on the FDA putting Juno's cancer clinical trial on hold. The "Fast Money" traders weigh in on the biotech sector.
CNBC's Meg Tirrell reports on Juno Therapeutics and the news that the FDA has put one of its cancer clinical trials on hold following two deaths during the trial.
U.S. cancer drug company Medivation is discussing opening its books to Sanofi, people familiar with the matter said on Tuesday.
CNBC's Meg Tirrell discusses biotech in the bear market and what to expect going forward.